MAP2K7 and cancer: Although the mechanisms behind these phenotypes are unclear, the results provide a rationale for investigating efforts to tailor the usage of MEK inhibitors for KRAS.G12V and KRAS.G12D–driven cancer treatments and highlight the importance of also considering the cytotoxicity of healthy cells when developing reagents against oncogenic KRAS signaling.